Given that JQ1 strongly upregulates ApoA1 in HepG2 cells, it can be used in combination with RVX-208 as a multitarget inhibitor in hepatocellular carcinoma [85]. This evidence concerns the gene APOA1 and hepatocellular carcinoma.